Results 301 to 310 of about 2,000,070 (348)
Some of the next articles are maybe not open access.
Standardization of Factor IX: Standards for "Purified" Factor IX Concentrates
Thrombosis and Haemostasis, 1991SummaryAn international collaborative study was carried out to determine the suitability of the current WHO II-IX-X concentrate standard, 84/681, for assigning potency to the more highly purified factor IX concentrates. Three Coagulation Factor IX (Human) preparations and one Factor IX Complex preparation were assayed by the one stage method against ...
M A, Lamb, W A, Fricke, S C, Rastogi
openaire +2 more sources
Thrombosis Research, 1986
Abnormal factor IX was isolated from the plasma of a patient with hemophilia B Kashihara and two patients with hemophilia BM. The F.IX was purified to homogeneity by using monoclonal anti-F.IX-Sephrose, heparin-Sepharose and DEAE-Sephadex A-50 affinity chromatography successively.
A, Yoshioka +7 more
openaire +2 more sources
Abnormal factor IX was isolated from the plasma of a patient with hemophilia B Kashihara and two patients with hemophilia BM. The F.IX was purified to homogeneity by using monoclonal anti-F.IX-Sephrose, heparin-Sepharose and DEAE-Sephadex A-50 affinity chromatography successively.
A, Yoshioka +7 more
openaire +2 more sources
Scandinavian Journal of Haematology, 1977
Fractionation technology has made Factor IX concentrates available. In addition to a very high incidence of hepatitis, thrombosis is being recognized as a consequence of their use. Contradictory reports exist in the literature as to the incidence of thrombotic events.
openaire +2 more sources
Fractionation technology has made Factor IX concentrates available. In addition to a very high incidence of hepatitis, thrombosis is being recognized as a consequence of their use. Contradictory reports exist in the literature as to the incidence of thrombotic events.
openaire +2 more sources
Factor IX activity and factor IX antigen in haemophilia B carriers
Thrombosis Research, 1975Abstract Examinations performed on the female relatives of haemophilia B patients suggest that factor IX activity is significantly reduced in the carriers of haemophilia B. In the carriers of haemophilia B− the amount of factor IX antigen is in correlation with factor IX activity, while in the carriers of the B+ variant the amount of factor IX ...
openaire +2 more sources
2009
Publisher Summary This chapter describes Factor IX (FIX) concentrates, which are either manufactured from human plasma pools or genetically engineered and FIX concentrates are indicated in treatment of hemophilia B. There are currently two plasma derived FIX concentrates available; AlphaNine SD and Mononine.
openaire +1 more source
Publisher Summary This chapter describes Factor IX (FIX) concentrates, which are either manufactured from human plasma pools or genetically engineered and FIX concentrates are indicated in treatment of hemophilia B. There are currently two plasma derived FIX concentrates available; AlphaNine SD and Mononine.
openaire +1 more source